This is incredibly cheap at $120mio USD. So I'm estimating anything between USD$400mio to $1bio is feasible on good Nash Ph2results & ensuing partnership agreement with big pharma.
Share price at 400/600/800/1bio market caps:
USD$400mio being ~$84 per share on Nasdaq or $2.67 on the Australian ASX
Market cap of USD$600mio being $126 per Nasdaq share or $4 on the ASX
USD$800mio ~$168 on Nasdaq or $5.34 ASX
USD$1bio ~$210, $6.67 on ASX
Personally I think a share price of north of $126 on Nasdaq is easily achievable on positive PH2 NASH & pharma collaboration within a few months afterwards. This also completely ignores the very promising preclinical Cdiff pipeline, which has commenced a Phase 1/2 on 60 patients.
Also on a cash side, Immuron will have funds from warrants & options exercising, & also cash lump sum payment from big pharma collaboration.
Keen to hear your thoughts on the market cap projections. Good luck and let's hope for amazing PH2 Nash results & a fantastic partnering deal with a chunky lump sum.
Recent IMRN News
- Immuron Director Resignation • GlobeNewswire Inc. • 05/03/2024 10:00:00 AM
- Immuron to host Live Virtual Event • GlobeNewswire Inc. • 04/15/2024 10:00:00 AM
- Immuron Travelan® sales continued strong growth • GlobeNewswire Inc. • 04/10/2024 10:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/07/2024 01:00:20 PM
- Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US • GlobeNewswire Inc. • 03/07/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/28/2024 01:08:13 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/21/2024 01:00:38 PM
- Immuron Presentation Australian Biologics Festival 2024 • GlobeNewswire Inc. • 02/21/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/13/2024 01:00:12 PM
- Immuron achieves record Travelan® sales • GlobeNewswire Inc. • 02/13/2024 11:00:00 AM
- Immuron CEO, Steven Lydeamore Investor Webinar Presentation • GlobeNewswire Inc. • 02/08/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/16/2024 01:00:11 PM
- Immuron achieves record half yearly Travelan® sales • GlobeNewswire Inc. • 01/16/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/22/2023 12:21:42 PM
- Immuron Clinical Trials Update • GlobeNewswire Inc. • 12/22/2023 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/04/2023 11:32:00 AM
- Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study • GlobeNewswire Inc. • 12/04/2023 11:00:00 AM
- Immuron CEO, Steven Lydeamore Investor Webinar Presentation • GlobeNewswire Inc. • 11/28/2023 11:33:14 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/28/2023 11:17:54 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/22/2023 12:16:44 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/21/2023 11:05:20 AM
- Immuron CEO Steven Lydeamore Investor Webinar Presentation • GlobeNewswire Inc. • 11/13/2023 11:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/13/2023 01:28:23 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/30/2023 12:00:17 PM
- Immuron CEO Steven Lydeamore presented at AusBioInvest • GlobeNewswire Inc. • 10/30/2023 11:21:17 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM